↓ Skip to main content

Dove Medical Press

Article Metrics

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders

Overview of attention for article published in Neuropsychiatric Disease and Treatment, November 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Readers on

mendeley
38 Mendeley
Title
Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
Published in
Neuropsychiatric Disease and Treatment, November 2012
DOI 10.2147/ndt.s14369
Pubmed ID
Authors

Nizar El-Khalili

Abstract

The atypical antipsychotic quetiapine fumarate is available both as an immediate release (IR) and as an extended release (XR) formulation allowing flexibility of dosing for individual patients. Approved uses of quetiapine XR include the treatment of schizophrenia (including maintenance therapy for prevention of relapse), the treatment of bipolar disorder (manic and depressive episodes), and the prevention of recurrence in patients with bipolar disorder who respond to quetiapine XR. This narrative review provides an update on quetiapine XR in these indications. The pharmacological profile of quetiapine, including a moderate affinity for dopamine D(2) receptors and higher affinity for serotonin 5-hydroxytryptophan (5-HT)(2A) receptors, may explain its broad efficacy and low propensity for extrapyramidal symptoms (EPS). The XR formulation has similar bioavailability but prolonged plasma levels compared with the IR formulation, allowing for less frequent (once-daily) dosing. Clinical studies have confirmed the efficacy of quetiapine XR in relieving the acute symptoms of schizophrenia during short-term trials, and reducing the risk for relapse in long-term studies. Direct switching from the IR formulation to the same dose of the XR formulation did not reveal any loss of efficacy or tolerability issues, and switching patients to quetiapine XR from conventional or other atypical antipsychotics (for reasons of insufficient efficacy or tolerability) also proved to be beneficial and generally well tolerated. In bipolar disorder, quetiapine XR has also proven effective in relieving acute depressive and manic symptoms. Adverse events with quetiapine XR in patients with either schizophrenia or bipolar disorder are similar to those associated with the IR formulation, the most common being sedation, dry mouth, somnolence, dizziness, and headache. The low propensity for EPS is maintained with the XR formulation. Overall, evidence from clinical trials suggests that quetiapine XR is an effective and generally well-tolerated treatment option in patients with schizophrenia and bipolar disorder.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 21%
Researcher 7 18%
Student > Doctoral Student 5 13%
Other 3 8%
Student > Master 3 8%
Other 8 21%
Unknown 4 11%
Readers by discipline Count As %
Medicine and Dentistry 20 53%
Psychology 6 16%
Nursing and Health Professions 4 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Chemistry 2 5%
Other 0 0%
Unknown 4 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2012.
All research outputs
#3,542,324
of 4,507,072 outputs
Outputs from Neuropsychiatric Disease and Treatment
#758
of 908 outputs
Outputs of similar age
#62,592
of 81,050 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#15
of 19 outputs
Altmetric has tracked 4,507,072 research outputs across all sources so far. This one is in the 3rd percentile – i.e., 3% of other outputs scored the same or lower than it.
So far Altmetric has tracked 908 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 81,050 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.